Ocuphire Pharma Q2 EPS $(0.24) Misses $(0.23) Estimate, Sales $3.67M Beat $2.42M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ocuphire Pharma reported Q2 losses of $(0.24) per share, missing the analyst consensus estimate of $(0.23) by 4.35 percent. However, the company's quarterly sales of $3.67 million beat the analyst consensus estimate of $2.42 million by 51.82 percent.
August 11, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ocuphire Pharma's Q2 earnings per share missed estimates, but sales exceeded expectations.
While Ocuphire Pharma's earnings per share missed estimates, the company's sales beat expectations, which could balance out the impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100